A new transatlantic partnership aimed at accelerating the growth of Irish health technology companies in the US has been agreed between Northwell Health and Enterprise Ireland.
The strategic alliance, signed in New York and witnessed by Minister for Enterprise Peter Burke, builds on an existing relationship between the two organisations dating back to 2016.
It is designed to support the commercialisation and scaling of Irish life sciences and medtech firms in the US market.
Northwell Health, one of the largest healthcare providers in the United States, is already working with 18 Enterprise Ireland-backed companies.
The collaboration has delivered outcomes including procurement contracts, clinical trials and investment through its venture arm.
As part of the announcement, Northwell also confirmed a separate partnership with Galway-based Neurent Medical, which is developing minimally invasive treatments for chronic rhinitis and related conditions.
The company recently raised €62.5m in an oversubscribed Series C funding round as it expands its presence in the US.
Enterprise Ireland said the renewed agreement would provide client companies with continued access to Northwell’s network of 28 hospitals and more than 1,000 outpatient facilities, alongside its clinical and commercial expertise.
Read more
Speaking at the signing, Burke said the partnership offers Irish firms a “critical gateway” into the US healthcare system, adding that Ireland’s life sciences sector is continuing to grow strongly.
Northwell’s executive director of global strategic partnerships, Elaine Brennan, said the organisation’s international programme has already proven effective in helping Irish companies establish themselves in the US, pointing to tangible outcomes such as pilot programmes and strategic investments.
Enterprise Ireland executive director Kevin Sherry said the deal reflects the strength of Ireland’s research and development ecosystem, noting that the country recorded €491m in life sciences and healthtech venture capital investment in 2024 despite a broader global slowdown.
The announcement comes alongside a series of expansion moves by Irish healthcare companies in the US market.
These include Shorla Oncology, which has grown its commercial operations, FIRE1, which has opened a US base, Head Diagnostics, which has secured new clinical partnerships, and X-Bolt, which has agreed a distribution deal with a major US healthcare network.
The expanded alliance underscores Ireland’s ambition to position itself as a global hub for life sciences innovation, with US partnerships playing a central role in bringing Irish-developed technologies to international markets.
* This article was originally published on BusinessPlus.ie.
Comments